Business Wire

Credorax Launches Cutting-edge Chargeback Prevention Solution

20.7.2021 14:13:00 EEST | Business Wire | Press release

Share

Leading smart payments provider and merchant acquiring bank, Credorax, has announced it is upping the ante in the world of fraud protection and chargeback mitigation by launching a cutting-edge solution to preventing chargebacks.

Credorax’s Chargeback PREVENTION marks a landmark partnership with Ethoca (owned by Mastercard), the leading, global provider of collaboration-based technology, and Verifi (a Visa solution), the leading provider of transaction risk management services for card-not-present merchants.

Merchants can now take control of their chargebacks by preventing chargebacks before they are initiated. Credorax’s innovative service offers merchants the ability to create rules that automate refunds or issue a manual refund after receiving an alert – both stop disputes from escalating to chargebacks.

Chargeback PREVENTION is part of the Credorax Risk Management suite and protects merchants from fraud and chargebacks through every stage of the transaction lifecycle. Credorax’s unique solution seamlessly combines the ingenuity of machine learning intelligence and intuitive data analysis to continually improve its fraud detection algorithm. It can accurately detect legitimate and fraudulent transactions on a large scale.

Depending on individual merchant needs and risk preferences, thresholds and rules management can be changed as and when necessary, tailored to the merchant’s unique requirements. Credorax also provides dedicated training to help merchants become familiar with Credorax’s fraud and chargeback prevention tools and optimise them based on a merchant’s particular specifications.

Drawing upon data from the world’s biggest ecommerce brands, banks, and payments providers, with Credorax’s Chargeback PREVENTION, merchants can view dashboards where they can monitor transactions, specific transaction rules and view alerts, giving them a complete overview their transaction lifecycles.

Moshe Selfin, Chief Technology Officer for Credorax, commented: “Ecommerce is booming, which means fraud and chargebacks rates are also accelerating – shockingly, merchant losses to friendly fraud were estimated to amount to over $50 billion in 2020. While far from ideal, the current state of play is undoubtedly driving levels of innovation and solution like we’ve never seen before. The sheer demand for turnkey, preventative fraud management systems, like ours, coupled with the advances in AI and real-time detection has the ability to put merchants on the front foot when dealing with fraudsters – a position they’ve never really been in before.

“With access to broadest possible range of bank issuer coverage globally, merchants have never been in a stronger position to armour themselves against the high costs and reputational hits that come with such attacks.”

Credorax is a full-service payments processor and acquirer dedicated to helping merchants by using cutting-edge technology and insights to bring innovative solutions to the market. Its payment experts are available to explain in more detail how you can benefit from its chargeback management and representation services.

Moshe added: “Our vision at Credorax has always been to provide merchants with the technology they need to take advantage of the global opportunities available to them. All while being safe in the knowledge that there are proactive and preventative measures in place that will make cross-border trading a pleasure and not a pressure.

“With a robust onboarding process that allows for an ongoing customer management journey with our specialist teams all over the world and a deep understanding of the nuances of payment processing, this is an exciting milestone in our ambition to further enhance Credorax’s exciting suite of offerings.”

For more information about Credorax’s Chargeback Prevention, visit: https://learn.credorax.com/contact-us .

#ENDS#

About Credorax

Credorax is a smart payments provider and fully licensed bank providing cross-border processing for eCommerce and omni-channel payments. Our core gateway technology, SourceTM, has been developed in-house to provide a streamlined payments experience so smart, that merchants can reach their full business potential simply by better managing their payments. Credorax merchants can accept more than a hundred cards and local payment methods and get paid in their currency of choice. Our merchants also enjoy best-in-class approval rate optimisation, advanced fraud protection, business intelligence and a host of other value-added services and products adding up to a payments experience unlike any other.

To learn more, contact us at grow@credorax.com or visit www.credorax.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Press Contact Credorax
Marisa Rijpkema
Head of Marketing, Credorax
Marisa.rijpkema@credorax.com
+31-6-42140533

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release

Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

SES Publishes FY2025 EU Taxonomy Restatement31.7.2026 08:30:00 EEST | Press release

SES today published a restatement of its FY2025 EU Taxonomy (Article 8) disclosure. The restatement updates the FY2025 EU Taxonomy disclosure included in the 2025 Annual Report and supersedes the previously published disclosure. The FY2025 EU Taxonomy Restatement is available on the SES website: https://www.ses.com/sites/ses_v2/files/investor-files/2026-07/EU_Taxonomy_Report_Restatement_2025.pdf Follow us on: X | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where they are. With integrated multi-orbit satellites and our global terrestrial network, we deliver resilient, seamless connectivity and the highest quality video content to those shaping what’s next. Following our Intelsat acquisition, we now offer more than 100 years of combined global industry l

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye